News & Events
Published On: 5/13/2021
Crohn’s & Colitis 360 Publishes Target RWE Inflammatory Bowel Disease Data
Disorders of the gastrointestinal (GI) track disrupt the lives of millions of Americans every day. Chronic inflammation of the GI tract is also known as inflammatory bowel disease, or IBD. An estimated 3 million adults in the U.S. have been diagnosed with one of the two most common types of IBD: Crohn’s disease and ulcerative colitis.1 Left untreated, IBD can lead to larger, more serious symptoms and complications. People with IBD are more likely to have other conditions including cardiovascular disease, respiratory disease, or liver disease, compared to people without an IBD diagnosis.1
Sponsored by Target RWE, TARGET-IBD (NCT03251118) is an ongoing observational, longitudinal study that gathers and analyzes real-world data (RWD) on IBD patient treatment and care over several years. The study’s RWD includes important information from patients themselves called patient-reported outcome measures (PROs) and biospecimen samples, or blood samples. TARGET-IBD’s first published manuscript detailing methodology and initial results has been recently published in the Crohn’s and Colitis Foundation’s peer-reviewed journal Crohn’s & Colitis 360 (https://doi.org/10.1093/crocol/otab023).
“IBD is a common inflammatory health condition, but data from large observational studies among diverse patients in a real-world setting is lacking,” said Julie Mallory Crawford, MD, Senior Director of Scientific & Medical Affairs, Target RWE. “TARGET-IBD gives us insight into disease severity in different care settings, treatment patterns, and clinical outcomes. Research using this valuable data can influence the way that providers care for their IBD patients in real and meaningful ways.”
The TARGET-IBD initial study results included 1,343 IBD patients enrolled over the first year from 27 academic and community sites throughout the United States. Of these, 60.1% were diagnosed with Crohn’s disease and 38.9% were diagnosed with ulcerative colitis. Baseline PROs were provided by 48.7% of the cohort and 62.6% provided a biosample.
Learn more about TARGET-IBD here.
1Centers for Disease Control and Prevention: https://www.cdc.gov/ibd/data-statistics.htm
About Target RWE
Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.
Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit www.targetrwe.com.
984.234.0268 ext 205
06/24/2022Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022
06/17/2022Target RWE Leads Industry Discussion of Fusion Designs and Teaching Advanced Epidemiologic Methods at SER 2022
05/22/2022New Data Presented at DDW 2022 Shows Nearly Two-Fold Risk of Loss of Remission in Ulcerative Colitis Patients Who Had Histologic Inflammation on Baseline Biopsy
05/20/2022Target RWE’s Allison Chandler Named One of Triangle Business Journal’s “40 Under 40”
04/04/2022Target RWE Primary Biliary Cholangitis (PBC) Encore Data Presented at APASL 2022